A TGA finding against compressed air can stop your production for weeks. A critical non-conformance can suspend your manufacturing licence. Lost-batch and downtime costs on a serious finding can run into the hundreds of thousands of dollars before the remediation contractor bills an hour. Compressed air is a recurring focus in TGA GMP inspections, because it is easy to treat as a background utility rather than the critical GMP system it is under PIC/S PE009-17.
This guide maps the actual TGA expectation to specific compressed air decisions: which ISO 8573-1 classes to specify for which contact level, how to qualify the system under PIC/S Annex 15, what your Contamination Control Strategy needs to cover after the 1 September 2025 Annex 1 transition, and where the recurring audit findings sit. The clause cites are quoted from the source documents; the ISO 8573-1 class numbers are risk-based industry recommendations, since PIC/S and the TGA do not prescribe specific ISO classes. The framing assumes you know your way around a GMP file and want straight answers, not regulatory ceremony.
By Byron Raal, CAS Founder-Editor · Last updated 5 July 2026 · About the author
What a TGA finding actually costs you
The TGA is the regulator. PIC/S sets the GMP framework Australia follows. Both fit together. But the working question for a plant manager isn’t “what does the regulator say?” It’s “what stops production if I get this wrong?”
Compressed air touches the product in more places than most operators realise: tablet coating, fluid bed drying, vessel pressurisation, conveyor blow-off, packaging line air, and, indirectly, instrument air on critical control loops, which affects product quality through process control rather than direct contact. Contaminated air at any of those points can put a batch on hold, force a deviation investigation, trigger a recall, or escalate into licence suspension.
TGA auditors assess compressed air under the utility qualification programme. A finding can move from observation to critical non-conformance fast if you can’t show the air quality is controlled, monitored, and documented. In the worst case, TGA can direct you to cease manufacturing until the deficiency is resolved. Two weeks of stop-manufacture on a busy site burns more than the cost of a proper compressed air requalification by an order of magnitude. That’s the dollar argument for getting this right before the audit, not after.
What changed when Australia adopted PIC/S PE009-17
The PIC/S Guide to Good Manufacturing Practice for Medicinal Products (PE009-17) became binding for Australian pharmaceutical manufacturers on 1 September 2025. It pulls through the revised Annex 1 on sterile medicinal products, and Annex 1 reframes compressed air as a critical utility that needs a documented Contamination Control Strategy. If you’re still operating against pre-2025 commissioning data with no current CCS, you’re carrying audit risk.
Three sections of the PIC/S Guide drive the compressed air decisions on your floor.
Part I, Chapter 3 (Premises and Equipment) requires premises and equipment, including supporting services, to be designed and maintained to minimise contamination risk; the formal qualification and monitoring of utilities that affect product quality is set out in Annex 15. Compressed air is in scope. The system must minimise contamination risk through appropriate filtration and drying at points of use.
Annex 1 (Manufacture of Sterile Medicinal Products) now requires a formal Contamination Control Strategy (CCS) covering every utility that contacts product or aseptic environment. Compressed air and process gases must be in the CCS, with risk assessments setting air quality at each point of use.
Annex 15 (Qualification and Validation) sets the IQ/OQ/PQ framework for compressed air systems. Ongoing requalification and routine monitoring follow, scaled to risk.
The CCS for compressed air: what Annex 1 actually requires
A compliant CCS for compressed air documents how your system prevents particulate, microbial, chemical, and cross-contamination risks across its lifecycle, intake to point-of-use. Eight things it has to cover.
- Intake air quality assessment (proximity to traffic, exhausts, or other contamination sources).
- Compressor technology selection rationale (oil-free vs oil-injected) with documented justification.
- Filtration train specification, including redundancy considerations.
- Dryer selection and pressure dew point justification.
- Distribution pipework materials and dead leg control strategy.
- Point-of-use filter integrity testing programme.
- Microbiological monitoring frequency with trigger thresholds.
- Out-of-specification response procedure, including batch impact assessment.
PIC/S PE 009-17 Annex 1 doesn’t prescribe a specific document name or single-deliverable format for the CCS. A clear standalone CCS document is industry best practice, not a regulator-set requirement. The reason to do it that way is practical: it makes the contamination-risk logic legible to auditors, simplifies internal training, and removes the audit risk of CCS evidence being scattered across the Site Master File, qualification reports, and SOPs in a way that obscures the logic.
If you produced ad-hoc CCS material under the older Annex 1 (PE009-14 and earlier), consolidating it into a single current document is a defensible gap-closure exercise. Build it with engineering, QA, and microbiology over three to six months. Sign-off at the site quality council. Review annually and on any change to compressor, dryer, filtration, or distribution that could affect sterile product quality.
Two air types you must distinguish
Medicinal air and utility compressed air sit on completely separate regulatory pathways. Confusing them is an audit-blocker.
Medicinal air is a therapeutic good under the Therapeutic Goods Act 1989. It needs an Australian Register of Therapeutic Goods (ARTG) listing and a separate TGA licence for medicinal gas manufacture. The TGA’s medicinal gases guidance sets out specific requirements for production, testing, and release of medicinal air intended for patient administration. If you’re supplying medical air for patient breathing, you’re in the medicinal gases pathway, and this page isn’t your reference.
Utility compressed air is a process utility used in manufacturing operations. No ARTG listing required. But it must comply with GMP requirements for critical utilities under the PIC/S Guide. You define air quality specifications based on a risk assessment of each application, qualify the system, and run an ongoing monitoring programme.
This page is about utility compressed air. Most TGA audit findings on compressed air concern utility systems, not medicinal gas installations.
ISO 8573-1 class targets by product contact level
The PIC/S Guide doesn’t prescribe specific compressed air quality classes. It requires you to define specifications from a documented risk assessment. The pharmaceutical industry uses ISO 8573-1:2010 as the reference standard for specifying and testing compressed air quality.
ISO 8573-1 expresses air quality as three separate class numbers (particles, water, oil) written as X.Y.Z. The class you need depends on how compressed air contacts the product.
| Contact Level | Typical Application | ISO 8573-1 Class | Key Requirements |
|---|---|---|---|
| Direct product contact | Tablet coating, fluid bed drying, vessel purging, product conveying | 1.2.1 | Oil-free compressor typical. Desiccant dryer to -40 °C PDP minimum. Sterile grade final filtration at point of use. |
| Indirect contact (product contact surfaces) | Equipment cleaning blow-down, autoclave air supply, isolator air | 2.4.2 (industry view; site-validated under quality risk assessment, not PIC/S-prescribed) | Oil-free preferred. Refrigerated dryer acceptable for moisture (+3 °C PDP) where Class 4 water is sufficient under site validation. Particulate filtration to 0.01 µm. |
| Non-contact utility | Instrument air, pneumatic actuators, general plant services | 3.4.3 (industry view; site-validated under quality risk assessment, not PIC/S-prescribed) | Oil-injected compressor with coalescing filtration acceptable. Refrigerated dryer sufficient. |
| Sterile applications | Aseptic filling line, sterile powder handling | 1.1.1 or 1.1.0 | Oil-free compressor. Deep desiccant drying to -70 °C PDP. 0.2 µm sterile membrane filter with integrity testing. |
The three numbers represent: particles (Class 1 permits a maximum of 20,000 particles at 0.1 to 0.5 µm per cubic metre), water (Class 2 requires a pressure dew point of -40 °C or lower), and oil (Class 1 limits total oil to 0.01 mg/m³ or less). Each class is defined independently. You specify all three on a risk-assessed basis.
Two mistakes recur. First, specifying a single combined “Class 2” for pharmaceutical air. ISO 8573-1 always requires three separate class numbers; the combined-class shorthand isn’t valid. Second, assuming a refrigerated dryer can deliver the water class needed for direct product contact. A refrigerated dryer achieves +3 °C pressure dew point at best, which is Class 4 water. Direct product contact applications needing Class 2 water (-40 °C PDP) need a desiccant dryer, full stop.
Specifying a TGA-compliant system
A pharmaceutical compressed air system that meets TGA GMP requirements has five components, each sized against your risk assessment and air quality specifications.
Oil-free compressor. For applications where compressed air contacts the product or product-contact surfaces, the design target is ISO 8573-1:2010 Class 1 oil (≤0.01 mg/m³ total oil including aerosol and vapour). ISO 8573-1 is a classification framework, not an equipment specification. Class 1 can be reached either with a true oil-free (Class 0 lubricant) compressor, or with an oil-lubricated compressor followed by a coalescer-polisher stack plus activated-carbon adsorber, provided the achieved oil content is verified by ISO 8573-2 (aerosol) and ISO 8573-5:2025 (vapour) testing.
ISO 8573-1 Class 0 is a separate beast. Class 0 has no fixed numeric value. The standard requires you to specify a stricter threshold than Class 1 and document both the equipment selected to achieve it and the validation programme that confirms it. Class 0 is a documentation and validation exercise, not the result of installing a particular filter stack. A coalescer-polisher train alone doesn’t entitle a system to a Class 0 claim. For sterile injectables, ophthalmics or inhalation products where Class 0 is appropriate, the typical configuration is a Class 0-lubricant oil-free compressor backed by redundant 0.01 µm coalescing filtration, an activated-carbon adsorber, point-of-use sterile filtration, and a validation programme that includes routine ISO 8573-2 and ISO 8573-5:2025 measurement against the user-defined threshold.
Oil-injected compressors with downstream coalescing filters are fine for non-contact utility air, but they introduce a residual oil risk that you have to manage through monitoring.
Desiccant dryer. Direct product contact applications need a desiccant dryer capable of -40 °C pressure dew point (ISO 8573-1 Class 2 water) or lower. Heatless desiccant dryers are the most common kit in pharmaceutical installations. Sterile applications may require deep desiccant drying to -70 °C PDP (Class 1 water). A refrigerated dryer (+3 °C PDP, Class 4 water) suits non-contact utility air, and indirect-contact uses only where a validated Class 4 water specification is sufficient.
Sterile filtration. Point-of-use sterile filters (0.2 µm membrane) are required for aseptic applications and recommended for direct product contact. These filters must be integrity tested (bubble point or diffusion test) at defined intervals, with results recorded. Upstream coalescing filters (0.01 µm) remove oil aerosol and fine particulate before the sterile filter.
Distribution pipework. Pharmaceutical compressed air distribution uses electropolished stainless steel (316L) or high-purity aluminium piping with orbital-welded or compression fittings. Dead legs minimised. The system designed for Clean-In-Place (CIP) or Steam-In-Place (SIP) capability where the CCS requires.
Monitoring points. Permanent monitoring or sampling points at compressor outlet, after each treatment stage (dryer, filters), and at representative points of use. Online monitoring for dew point and particle count is increasingly used by pharmaceutical manufacturers for direct product contact applications, and it’s well regarded at audit because it produces continuous trend data rather than spot samples.
For a facility running a 75 kW oil-free compressor at 8 bar for 16 hours per day, electricity costs alone reach approximately $131,400 per year at Australian industrial rates (approximately $0.30 per kilowatt-hour as of 2026; actual rates vary by state, tariff, and contract). Energy is typically 70 to 80 percent of a compressor’s total cost of ownership over ten years. Right-sizing the system and minimising leaks through a structured leak detection programme is where the operating-cost discipline lives.
Need help specifying a TGA-compliant compressed air system?
Tell us your product types (sterile injectables, tablet manufacture, dry powder, ophthalmic, inhalation, OTC liquid, etc.), your current compressor make and rated kW, your current dryer type, your last TGA inspection date, your state and suburb, and a one-line description of what’s prompting the call. We acknowledge inside one business day. Within five business days we come back with a shortlist of compressed air designers, oil-free compressor suppliers, NATA-accredited testing providers, and pressure-vessel inspection engineers whose pharma experience matches your scope, or a status update.
Qualification, monitoring, and documentation
TGA auditors expect a lifecycle approach: qualified to PIC/S Annex 15 at install, requalified on change, monitored continuously, documented end to end.
System qualification (IQ/OQ/PQ)
Installation Qualification (IQ) verifies the compressed air system was installed against the approved design specification. Equipment models, materials of construction, piping layout, weld certifications (for stainless steel), filter specifications, and instrumentation calibration certificates.
Operational Qualification (OQ) demonstrates that the system operates within specified parameters across its operating range. Discharge pressure, flow capacity, dew point at each treatment stage, particle counts, and oil vapour concentration. OQ testing covers normal operating conditions, maximum demand, and relevant upset scenarios.
Performance Qualification (PQ) confirms the qualified system consistently delivers air meeting the specified ISO 8573-1 classes under actual production conditions. PIC/S Annex 15 frames PQ as demonstration that the system performs reliably across its intended operating range; it doesn’t prescribe a fixed number of production campaigns or a calendar duration. Duration and scope of PQ data collection sit in the validation master plan and get justified against your facility’s risk profile and product impact.
Ongoing monitoring
After qualification, the compressed air system needs routine monitoring. PIC/S PE 009-17 frames monitoring frequency and parameter scope as risk-based, determined by your CCS. The frequencies below are common industry practice for Australian pharmaceutical sites and are useful as a starting point, not a regulator-set requirement. The actual cadence at your site has to be justified by your risk assessment and recorded in the CCS.
| Parameter | Test Method | Common Industry Frequency (risk-justify per site) | Acceptance Criteria |
|---|---|---|---|
| Dew point | Online hygrometer or manual spot check | Continuous (online) or weekly (manual) | Per ISO 8573-1 water class at each point |
| Particle count | Laser particle counter per ISO 8573-4 | Quarterly at points of use (risk-justify) | Per ISO 8573-1 particle class |
| Oil content (aerosol + vapour) | Coalescing or sampling collection with infrared or gas chromatography per ISO 8573-2 (aerosol) and thermal desorption gas chromatography per ISO 8573-5:2025 (vapour) | Quarterly at points of use (risk-justify) | Per ISO 8573-1 oil class |
| Microbiological | Impaction or filtration sampling | Risk-based per the site’s Contamination Control Strategy. PIC/S Annex 1 requires periodic point-of-use microbial monitoring; common industry cadence ranges monthly (highest risk) to annually (lowest risk) depending on contact zone and historical data. | Facility-defined limits based on risk assessment |
| Filter integrity | Bubble point or diffusion test | After each filter change and six-monthly (risk-justify) | Per filter manufacturer specification |
All monitoring results get recorded, trended, and reviewed. Out-of-specification results trigger a deviation investigation under your quality management system. The investigation assesses potential impact on every batch manufactured since the last passing result. That’s where calendar-only monitoring catches people: by the time the point-of-use test fails, the back-investigation scope is bigger than the original audit risk.
Documentation
TGA auditors review compressed air documentation as part of the utility qualification file. The essential set: User Requirements Specification (URS), risk assessment for air contact classification, qualification protocols and reports (IQ/OQ/PQ), routine monitoring SOPs and results, preventive maintenance schedules and records, filter change-out and integrity test logs, deviation reports and CAPA records, change control records for any system modification, and annual Product Quality Reviews (PQRs) that include compressed air trend data.
Change control matters more than most plant managers think. Any modification to the compressed air system, whether replacing a compressor, changing filter grades, altering piping, or adjusting monitoring frequency, goes through change control with a documented impact assessment and, where necessary, requalification. Skip the change control and your next deviation surfaces a compounding finding: the engineering change, plus the absence of impact assessment, plus the absence of requalification.
Where TGA audits actually find against compressed air
Several findings recur across pharmaceutical manufacturing sites in Australia. Most are documentation gaps rather than engineering failures, which means they’re fixable inside 60 days if the plant is otherwise in order.
No documented risk assessment for air contact classification. The site uses compressed air in multiple applications but hasn’t formally assessed which involve direct product contact, indirect contact, or non-contact. Without that assessment, air quality specifications can’t be justified and the monitoring programme has no basis.
Qualification documentation incomplete or missing. The system was commissioned but never formally qualified under IQ/OQ/PQ. Or the original qualification exists but the system has been modified (compressor replacement, piping extension) without requalification through change control.
Monitoring programme inadequate. Monitoring limited to dew point only, no particle or oil testing. Or testing performed annually rather than at the risk-justified cadence. Or monitoring points don’t cover all critical points of use. Some sites test at the compressor room outlet but not at points of use, which misses contamination introduced by the distribution system.
Wrong dryer type for the application. A refrigerated dryer installed on a system supplying direct product contact air, but the risk assessment specifies Class 2 water (-40 °C PDP). The refrigerated dryer achieves +3 °C PDP at best (Class 4 water). The gap between specification and capability is what the auditor finds.
Filter management failures. Sterile filters not integrity tested after installation. Filter change-out intervals based on calendar time alone without considering differential pressure monitoring. No traceability between filter serial numbers and the specific point-of-use location.
No trending of monitoring data. Results recorded but never trended or reviewed. Gradual deterioration in air quality, increasing particle counts, rising dew point, goes undetected until a point-of-use test fails. By then, multiple batches manufactured since the last passing result are in investigation scope.
Testing not by NATA-accredited laboratory. NATA accreditation isn’t a TGA requirement. But using a NATA-accredited laboratory strengthens the defensibility of your monitoring data during audits because the laboratory’s accredited scope is documented and traceable to ISO/IEC 17025. Auditor acceptance of any test result still depends on the laboratory’s scope covering the specific ISO 8573 parts referenced in your HACCP plan or CCS. Confirm the NATA scope document with the provider before engagement.
Australian-specific requirements on top of PIC/S
PIC/S GMP gets you national alignment. Australia adds three pieces you have to satisfy on top.
Pressure vessel hazard level and registration. Air receivers and other pressure-containing components in a compressed air system must be assessed against AS 4343:2014 (Pressure Equipment - Hazard Levels). Hazard level is calculated using H = P × V × Fc × Ff × Fs, where P is design pressure, V is volume, and Fc, Ff, Fs are factors covering fluid contents, fluid characteristics, and operating conditions or service. The resulting hazard level (A through E) is then read together with the state or territory model WHS Regulations Schedule 5 Part 1 (design registration) and Schedule 5 Part 2 (item registration) to determine which pressure vessels require registration. AS 1210:2010 covers design and construction of pressure vessels; it’s the parent design standard, not the registration threshold. Failure to follow the AS 4343 + state WHS pathway is a separate regulatory breach that can compound a GMP finding.
NATA-accredited testing. The National Association of Testing Authorities (NATA) accredits laboratories and testing organisations against ISO/IEC 17025. For pharmaceutical compressed air, NATA accreditation is available for ISO 8573-4 (particle testing), ISO 8573-3 (moisture measurement), and ISO 8573-2 and ISO 8573-5:2025 (oil aerosol and vapour). Using a NATA-accredited provider strengthens the defensibility of your monitoring data during a TGA audit; auditor acceptance of any specific result still depends on the laboratory’s accredited scope covering the relevant ISO 8573 parts.
TGA auditor approach. The TGA is a member of PIC/S, and its GMP inspectors are trained to the same standards as European inspectors. They look for a lifecycle approach to compressed air, design qualification through to ongoing monitoring, with complete traceability. Australian pharmaceutical manufacturers are also subject to unannounced inspections, which makes continuous compliance the practical operating mode rather than audit preparation alone.
State and territory variations. TGA GMP is national. Pressure equipment registration, workplace health and safety obligations, and environmental permits for compressor noise and condensate discharge are administered by state and territory authorities. You satisfy both layers, not one.
Frequently Asked Questions
What ISO 8573-1 class do I need for direct-contact pharmaceutical air?
For compressed air with direct product contact in a sterile or non-sterile pharmaceutical process, the default Australian industry practice is ISO 8573-1 Class 1 for particles, Class 2 for water, and Class 1 for oil, written 1.2.1. Where the product must remain oil-free (injectables, ophthalmic, inhalation), move oil to Class 0 with a written oil-free specification and a validation programme. For indirect contact (vial rinsing upstream of sterilisation), Class 2.4.2 is usually defensible. Non-contact (instrument air) is typically 3.4.3. The class choice has to be tied to a site risk assessment, not a vendor default; PIC/S PE 009-17 doesn’t prescribe a specific ISO 8573-1 class for pharmaceutical compressed air.
What changed when Australia adopted PIC/S PE009-17?
PIC/S Guide to GMP PE009-17 took effect for Australian pharmaceutical manufacturers on 1 September 2025. It pulled through the revised Annex 1 on sterile product manufacture, which reframes compressed air as a critical utility and requires a documented Contamination Control Strategy (CCS) that explicitly covers it. In practice, compressed air for sterile product contact needs risk-based classification, routine monitoring, deviation management, and a maintained audit trail, not just a one-off commissioning test. Sites still running pre-2025 commissioning data should treat consolidation into a current CCS as a priority.
Does Annex 1 actually require a contamination control strategy for compressed air?
Yes. Annex 1 is explicit that the CCS must cover every utility that contacts product or product-contact surfaces, and compressed air almost always does one or both. The CCS identifies the points of use, the contamination risks at each (particles, water, oil, viable organisms), the controls applied (filtration stages, dryer type, sampling frequency), and how those controls are verified. PIC/S doesn’t prescribe a single-document format for the CCS, but a clear standalone CCS document is industry best practice because it makes the contamination-risk logic legible to auditors and removes the audit risk of evidence being scattered across the Site Master File and SOPs.
How often does pharmaceutical compressed air need to be retested?
PIC/S PE 009-17 frames monitoring frequency as risk-based, determined by the site’s Contamination Control Strategy, not a universal cadence. Common Australian industry practice is annual full ISO 8573-1 requalification for particles, water and oil plus quarterly microbial sampling at every product-contact use point, but those frequencies have to be justified by the facility’s risk assessment, not adopted by default. Change-driven re-testing also applies: after filter changes, dryer service, distribution changes, or any deviation that could affect air quality. Each point of use is its own qualification.
What are the most common TGA audit findings on compressed air?
The recurring findings, in rough order of frequency: (1) CCS doesn’t list compressed air as a covered utility, (2) sampling frequency not justified by risk assessment, (3) test scope missing microbial or oil where contact risk is present, (4) commissioning certificate being used years after install with no requalification, (5) filter change records not linked to requalification, and (6) sample port locations that don’t represent the worst-case use point. Most are documentation gaps rather than engineering failures, which means they’re fixable inside 60 days if the plant is otherwise in order.
Who performs the testing, in-house or NATA-accredited?
Microbial and total particle counts can be run in-house with validated equipment and trained personnel, provided the method is documented and the results are treated as GMP records. Oil content (Class 0 or Class 1 claims) and formal ISO 8573-1 requalification are commonly run by a NATA-accredited laboratory against ISO/IEC 17025 because the NATA scope documentation strengthens audit defensibility. The in-house-versus-NATA split is a commercial call; monthly microbial in-house plus annual NATA requalification is a common middle ground for a mid-size Australian site, but the actual split has to be supported by the site’s risk assessment and documented in the quality system.
Related Resources
- Pharmaceutical Industry Compressed Air Guide
- Compressed Air Filtration: Australian Specification Guide
- Oil-Free Compressors: Australian Specification Guide
- Compressed Air Dryers and Air Quality
- Compressed Air System Design Guide
- FSANZ Food Contact Compressed Air Requirements Guide (sister regulatory page)
- Air Receiver Tanks Australia: AS 4343:2014 hazard level + state WHS registration pathway
External References
- TGA: GMP Requirements for Medicinal Products (PIC/S PE009-17)
- PIC/S: Guide to Good Manufacturing Practice Publications
- Standards Australia: AS ISO 8573-1:2010 Compressed Air Quality Classes
- Standards Australia: AS 4343-2014 Pressure Equipment Hazard Levels
- NATA: National Association of Testing Authorities Australia
- Safe Work Australia: Pressure Equipment Requirements
- Dew point calculator: Verify your point-of-use pressure dew point against the ISO 8573-1 water class your CCS targets
Get matched with a TGA-compliant compressed air supplier
Tell us your product types, your current compressor make and rated kW, your current dryer type, your last TGA inspection date, your state and suburb, and one line on what’s prompting the call (TGA finding, capex window, scope-creep deviation, audit prep, regulatory review). We acknowledge inside one business day. Within five business days we come back with a shortlist of compressed air designers, oil-free compressor suppliers, NATA-accredited testing providers, and pressure-vessel inspection engineers whose pharma experience matches your scope, or a status update.
General information disclaimer. The information on this page is general in nature and provided for educational purposes only. It is not engineering, safety, or professional advice, and it does not account for the specifics of your site, equipment, or duty. Compressed air system design, pressure equipment selection, and regulatory compliance must be confirmed with a qualified engineer and the relevant work health and safety regulator before you act. Compressed Air Solutions is a publisher and referral service, not a licensed engineering practice, and accepts no liability for decisions made on the basis of this content. Verify all figures, standards references, and regulatory requirements against current primary sources.